Keywords: Acute coronary syndrome, Generic erosion, Decision Resources, AstraZeneca, Brilinta, Merck & Co, GlaxoSmithKline, Integrilin

Generic erosion of key high-priced brands will see acute coronary syndrome drug market fall 12% to $809 million in 2016

Article | 03 November 2010

Print This

As a result of generic erosion of key high-priced brands, the acute coronary syndrome drug market will decline from approximately $923 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in